Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company at the start of medical cannabis journey, says interim chairman

THC aims to provide access to high-quality legal medical cannabis enabling many to lead better lives by relieving pain and suffering.
Cannabis growing facility
The growing facility in Queensland is awaiting approvals before starting cultivation

The Hydroponics Company Ltd (ASX:THC) is at the start of a journey that will provide access to high-quality legal medical cannabis and enable many to lead better lives by relieving pain and suffering.

Interim chairman Steven Xu said that THC’s success would be judged not only on successful corporate actions and great deals, but also on the benefits and developments it brings.

READ: The Hydroponics Company makes board and management changes, shares jump

“A strong share price, satisfied shareholders and healthy dividends will naturally follow,” he said at the company’s inaugural annual general meeting.

“The development, production and supply of medical cannabis presents tremendous opportunities for growth for THC.

“Having assessed many medical cannabis companies worldwide for investment potential, I identified THC as providing a measured investment opportunity through its existing revenue prospects and clear direction,” Xu said.

Interim chairman’s report

Following are extracts from the interim chairman’s report:

It is less than 18 months since the provision of medical cannabis was legalised via changes to Australian legislation.

Since listing in 2017, THC has moved forward to bring world’s best product to Australia, while simultaneously establishing local capability to build local supply and export potential.

READ: The Hydroponics Company granted approval to import medicinal cannabis products

My fellow director Alan Beasley has researched the benefits of alternative medical treatments, including medical cannabis, for over a decade and this is a personal journey for him.

We believe medical cannabis will be a game changer for palliative care patients, sufferers of

Parkinson’s Disease, Tourette’s Syndrome, epilepsy, appetite loss and nausea for cancer patients and many other ailments.

Current medicines do not presently relieve these ailments or otherwise have side effects which may not be present in medical cannabis and can be used alongside current treatments.

Register has grown 700%

Our register has grown by over 700% since listing in May 2017 and THC now has close to 5,500 shareholders, up from 750 at listing.

Through our acquisition of Canndeo, we inherited over 17 years’ experience in the breeding, variety selection and growth management of Cannabis sativa.

This knowledge will be applied to the research, development and production of medical cannabis by THC.

We have been granted two of the three licences necessary.

The licences are issued by the Office of Drug Control and we look forward the grant of the third licence.

Growing facility in Queensland is ready

Our facility in Queensland is ready to commence cultivation of our pilot crop of medical cannabis, which will start immediately upon receipt of the appropriate government approvals.

The site has been developed to meet increasing demand for high-quality medical cannabis products for local and export markets.

Stage I of the development includes greenhouses for indoor cultivation and growth of medical cannabis, a drying and shredding facility for the initial processing of the dried plants, and an extraction laboratory for the processing of crude extract from the shredded plants.

The site will also provide an onsite laboratory for the development of new strains, as well as testing and quality control of harvested products.

The site, when fully optimised, will be scalable to meet the demands of a growing market.

Supplier agreements secured

THC has reached out and secured agreements with two leading suppliers of medical cannabis – Endoca in Denmark and BOL Pharma in Israel, each with many years’ experience and knowledge in the production of medical cannabis.

Import permits have been granted to allow the first import by THC of medical cannabis from our European partner Endoca.

Patients in Australia will have immediate access under the existing government Special Access Scheme or through an Approved Prescriber and we expect the first products to arrive from Endoca shortly.

THC will continue investigating National Access Clinics to the extent allowed by Australian regulation.

We will be working with Wesley Medical Research in their conduct of research in Tourette’s Syndrome.

We will provide medical cannabis from BOL Pharma for this purpose with the trial to commence in the second quarter this year.

BOL Pharma will also supply THC medical cannabis for general patient access once their local regulations permit and supply agreements are in place.

READ: The Hydroponics Company increases warehousing in Canada to facilitate expansion in supply

THC is keen to grow its Canadian business and has commenced a process to identify businesses that offer a synergy to THC.

Through THC’s acquisition of Crystal Mountain, our Canadian business, we have revenue from manufacturing, supply and distribution networks with strong prospects for growth.

We are working diligently to increase their product range, expand warehouse facilities and improve the online presence. We have recently expanded the sales force.

THC continues to conduct due diligence and negotiate terms for the acquisition of an additional Canadian company in the same space.

This business is complementary to the existing Crystal Mountain-Dragon Vision business and provides exposure to the rapidly growing licensed producers in the eastern states of Canada.

The future for THC is positive. We are working in a nascent disruptive industry, that will develop and grow exponentially.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full THC profile View Profile

Hydroponics Company Ltd Timeline

Related Articles

Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use